Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

BACKGROUND

POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific data about the activity and efficacy of immune checkpoint inhibitors (ICIs) in POLE/D1pd mCRC are lacking and it is unknown whether outcomes may be different from mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) mCRCs treated with ICIs.

PATIENTS AND METHODS

In this global study, we collected 27 patients with mCRC harboring POLE/D1 mutations leading to proofreading deficiency and treated with anti-programmed cell death-ligand 1 alone +/- anti-cytotoxic T-lymphocyte antigen-4 agents. We collected clinicopathological and genomic characteristics, response, and survival outcomes after ICIs of POLE/D1pd mCRC and compared them with a cohort of 610 dMMR/MSI-H mCRC patients treated with ICIs. Further genomic analyses were carried out in an independent cohort of 7241 CRCs to define POLE and POLD1pd molecular profiles and mutational signatures.

RESULTS

POLE/D1pd was associated with younger age, male sex, fewer RAS/BRAF driver mutations, and predominance of right-sided colon cancers. Patients with POLE/D1pd mCRC showed a significantly higher overall response rate (ORR) compared to dMMR/MSI-H mCRC (89% versus 54%; P = 0.01). After a median follow-up of 24.9 months (interquartile range: 11.3-43.0 months), patients with POLE/D1pd showed a significantly superior progression-free survival (PFS) compared to dMMR/MSI-H mCRC [hazard ratio (HR) = 0.24, 95% confidence interval (CI) 0.08-0.74, P = 0.01] and superior overall survival (OS) (HR = 0.38, 95% CI 0.12-1.18, P = 0.09). In multivariable analyses including the type of DNA repair defect, POLE/D1pd was associated with significantly improved PFS (HR = 0.17, 95% CI 0.04-0.69, P = 0.013) and OS (HR = 0.24, 95% CI 0.06-0.98, P = 0.047). Molecular profiling showed that POLE/D1pd tumors have higher tumor mutational burden (TMB). Responses were observed in both subtypes and were associated with the intensity of POLE/D1pd signature.

CONCLUSIONS

Patients with POLE/D1pd mCRC showed more favorable outcomes compared to dMMR/MSI-H mCRC to treatment with ICIs in terms of tumor response and survival.

Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience

PURPOSE

Subset analyses from phase III evaluation of epidermal growth factor receptor inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA), but large-scale analyses are lacking. This multi-institutional analysis sought to determine the role of EGFRi in the largest cohort of patients with EGFR-amplified GEA to date.

PATIENTS AND METHODS

A total of 60 patients from 15 tertiary cancer centers in six countries met the inclusion criteria. These criteria required histologically confirmed GEA in the metastatic or unresectable setting with EGFR amplification identified by using a Clinical Laboratory Improvement Amendments-approved assay, and who received on- or off-protocol EGFRi. Testing could be by tissue next-generation sequencing, plasma circulating tumor DNA next-generation sequencing, and/or fluorescence in situ hybridization performed by a Clinical Laboratory Improvement Amendments approved laboratory. Treatment patterns and outcomes analysis was also performed using a deidentified clinicogenomic database (CGDB).

RESULTS

Sixty patients with EGFR-amplified GEA received EGFRi, including 31 of 60 patients (52%) with concurrent chemotherapy. Across treatment lines, patients achieved a 43% objective response rate with a median progression-free survival of 4.6 months (95% CI, 3.5 to 6.4). Patients receiving EGFRi in first-, second-, and third-line therapy achieved a median overall survival of 20.6 months (95% CI, 13.5 to not reached [NR]), 9 months (95% CI, 7.9 to NR), and 8.4 months (7.6 to NR), respectively. This survival far exceeded the 11.2-month (95% CI, 8.7 to 14.2) median overall survival from first-line initiation of non-EGFRi therapy in patients with EGFR-amplified GEA in the CGDB. Despite this benefit, analysis of the CGDB (January 2011-December 2020) suggests that only 5% of patients with EGFR-amplified GEA received EGFRi.

CONCLUSION

Patients with EGFR-amplified GEA derive significant benefit from EGFRi. Further prospective investigation of EGFRi in a well-selected patient population is ongoing in an upcoming trial of amivantamab in EGFR and/or MET amplified GEA.

P975Composite electroanatomical maps locate rapid activity within low voltage zones in persistent AF

Funding Acknowledgements

Our research group receives an educational grant from Abbott Inc.

Introduction. Outcomes from catheter ablation of persistent AF (psAF) are not favourable. The two prevailing major directions to improve success are left atrial (LA) substrate ablation, and non pulmonary vein driver ablation. In LA substrate ablation guided by intracardiac voltage, there is debate on the most fitting mapping rhythm and the appropriate cut offs for low voltage zones (LVZ). Non pulmonary vein driver ablation requires extensive experience and relies on complex pattern recognition by the operator, introducing subjectivity, that may lead to reduced reproducibility. AF drivers have been shown to localise to LVZs. We propose an objective, patient-tailored method of identifying rapid activity within LVZs to locate drivers of psAF. 

Methods. Eleven patients (61 ± 10.8 years of age, 9 male) undergoing first time catheter ablation for psAF were included. 3D maps were collected with a double spiral 20 pole catheter, in non-cardiac triggered mode, recording 8s segments at each bipole. Mean AF voltage (AFV) a AF cycle length (AFCL) was calculated for each 8s segment using automated algorithms. Grades of rapid activity and low voltage were defined as the 10th 20th and 30th percentile of all collected points within a patient. Percentile-matched composite LVZ-ARA maps were created on a research platform. 

Results. Mean LVZ percentage of the total mapped area was 4.67 ± 2.4%, 13.95 ± 3.8%, 23.81 ± 5.7% for the 10th, 20th and 30th percentiles respectively (Table 1). Mean, percentile matched LVZ-ARA overlap area percentage of the total mapped area was 0.3 ± 0.25% (10th-10th), 0.86 ± 0.58 (20th-20th), 3.1 ± 1.9% (30th-30th). ARAs represented a small proportion of all LVZs. Location of overlap areas differed significantly between patients and were marked with colours. Multi-colour areas including purple represent LVZ, multi-colour areas excluding purple, show LVZ-ARA overlap (examples in Fig 1). 

Conclusion. Analysis of LVZ-ARA overlap by mean AFV and AFCL provides an objective method of identifying potential drivers that localise to LVZs. The identified overlap areas constituted small, occasionally disparate areas within the LVZ of the LA. By adjusting the AFCL and AFV percentiles, the overlap areas can be tailored at the operator’s discretion, maintaining reproducible, objective decision making, without the need for complex pattern recognition. If ablation is planned, established techniques can be used to target the overlap areas, such as homogenisation or transection and connection to anatomical or ablative non-conductive tissues.

AFCL 10th AFCL 20th AFCL 30th AFV 10th AFV 20th AFV 30th All patients 128 ± 13 ms 144 ± 10 ms 150 ± 9 ms 0.15 ± 0.02 mV 0.19 ± 0.03 mV 0.24 ± 0.04 mV Mean values of percentile cut offs. AFCL: AF cycle length; AFV: AF voltage

Abstract Figure. Fig 1

P991Pattern of rapid activity is preserved in persistent AF in selected locations after pulmonary vein isolation

Funding Acknowledgements

Our research group receives an educational grant from Abbott Inc.

Introduction. There is evidence to suggest that structural remodelling in psAF potentially gives rise to areas of rapid cycle length activity that may act as driving mechanisms. We describe a new method to compare rapid activity (RA) in psAF prior to and after pulmonary vein isolation, in extended AF segments (EAFS). We focus on patterns of RA, based on the hypothesis that AF drivers are transient but recur in the same locations. 

Methods. Five patients (61 ± 8 years of age, 3 male) for catheter ablation of psAF were included. 3D maps were collected with a double spiral 20 pole catheter. In stable locations, pre and post PVI, 37s EAFS were recorded using 8s segments, automatically every 1s, creating a 7s overlap between segments. Dominant cycle length (DCL) was determined for every 8s segment by a fully automated algorithm. RA was defined as the rapidest 20th percentile for each patient. RA episodes consisted of continuous segments with rapid DCL (black lines in Fig 1) and terminated with a non-rapid segment (red lines on Fig 1). Episodes were truncated where overlap occurred (Box 1 and Box 2 in Fig 1). The pattern of RA was assessed by the number, cumulative duration and mean duration of RA episodes within an EAFS pre and post PVI.

Results. Mean DCL of EAFS increased significantly in 4/5 patients after PVI, the number of EAFS with rapid activity showed a reduction in all patients.  The percentage of new sites with RA post PVI was 27%. The number of sites that retained RA post PVI was 14 ± 11.3 (58.3%; Table 1).  Of these, number and cumulative duration of RA did not change in 4/5 patients, and mean duration of RA remained stable in 5/5.

Conclusion. An automated DCL algorithm shows that, in most cases, global AFCL prolongs significantly with PVI overall, but selected foci retain RA and RA patterns. These may represent active drivers, as their activity appears to be independent of their surroundings.

Table 1 Patient ID Number of segments Mean AFCL ± SD of all segments Number of EAFS with rapid activity Pre-PVI Post-PVI P Pre-PVI Post-PVI New sites 1 145 135 ± 8.9 141 ± 9.8 <0.001 94 62 15 2 121 154 ± 12.9 162 ± 15.0 <0.001 94 72 11 3 172 148 ± 13.7 160 ± 16.6 <0.001 108 82 25 4 301 172 ± 22.9 174 ± 21.5 0.418 198 189 58 5 200 177 ± 9.9 215 ± 18.1 <0.001 87 43 14 Pre and Post PVI cycle length and EAFS with rapid activity. (AFCL: AF cycle length; EAFS: Extended AF segments; PVI: Pulmonary vein isolation)

Abstract Figure.